Hepatic Micro RNA Expression In Non Alcoholic Fatty Liver Disease
试验速览
- 阶段
- 不适用
- 入组人数
- 80
- 主要终点
- Descriptions of altered miRNA profiles in NAFLD patients especially with fibrosis.
研究概览
简要总结
- Epidemiological study of NAFLD, NASH patients.
- Descriptions of altered miRNA profiles in NAFLD patients especially with fibrosis. - Explore the role of circulating miRNAs as biomarkers for the early diagnosis and evaluation of NAFLD patient with fibrosis.
详细描述
Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic steatosis (>5%-10% of hepatocytes are fatty) in people without history of excessive alcohol consumption (>21 drinks/week in men and > 14drinks/week in women) and other disease etiologies that result in fatty liver.
The presence of coexisting risk factors such as diabetes, metabolic syndrome, and obesity increases the risk of NAFLD. As a consequence of obesity pandemic and type 2 diabetes, an increased number of patients with NASH-the most severe form of NAFLD-is expected in the near future.
According to the latest epidemiological studies, the prevalence of NAFLD is approximately 25% worldwide.
In developed countries such as the United States, the prevalence of NAFLD is 30%. In developing countries such as China, the prevalence has reached up to 32.9%.
NAFLD comprises a spectrum of pathological conditions, Including simple steatosis (NAFL), nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •Elevated aminotransferases
- •Ultrasonographic presence of hyper echogenic liver
- •fibroscan with a diagnosis of non-alcoholic fatty liver disease with fibrosis (NASH) without cirrhosis done no more than 6 months before the study.
排除标准
- •A history of any level of alcohol consumption
- •Any other form of chronic liver disease
- •Use of any medications thought to cause or affect NAFLD
- •Acute or chronic infection
- •History of cancer
- •Chronic kidney diseases
结局指标
主要结局
Descriptions of altered miRNA profiles in NAFLD patients especially with fibrosis.
时间窗: baseline
Explore the role of circulating miRNAs as biomarkers for the early diagnosis and evaluation of NAFLD patient with fibrosis
次要结局
未报告次要终点
研究者
Nourhan Mahmoud Abbas
Assistant lecturer at tropical medicine and gastroenterology department
Assiut University